Discontinue use and consult a medical doctor immediately if you experience unusual symptoms. Consult a medical doctor before use if you have been treated for, or diagnosed with or have a family history of any medical condition, or if you are using any prescription or over-the-counter drug(s), including blood thinners. Consult a medical doctor before starting any diet or exercise program. Improper use of this product will not improve results and is not advised. Use only as directed.
The FDA relies on applicants and scientific investigators to conduct research. Our role, as outlined in the Federal Food, Drug, and Cosmetic Act, is to review data submitted to the FDA in a marketing application to determine whether a proposed drug product meets the statutory standards for approval. Additional information concerning research on the medical use of marijuana is available from the National Institutes of Health, particularly the National Cancer Institute (NCI) and NIDA.
Many cells in the body have what are called cannabinoid receptors, protein molecules on a cell’s surface that react when they come in contact with certain chemical substances. Different receptors react with different substances to cause different reactions – for instance, the release of a hormone or other chemical. The cells that react with cannabinoids comprise what’s known as the endocannabinoid system. When these receptors are activated, they exert an effect on mood, pain sensation, appetite and other biologic responses.
Synthetic cannabinoids also pose a significant risk to users because the effects can be much more severe than those produced by marijuana. Some of the compounds in synthetic cannabinoids bind more strongly to brain receptors, which is why the effects could be more powerful and unpredictable. Moreover, synthetic cannabinoid products don’t always list every ingredient on the packaging label, so the effects of the product could be greater or different than expected.
In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [1, 2].
“CBD oil can contain some THC or it can contain none,” Romanowski says. “It really depends on how it is processed.” Regardless, though, it’s not enough to be psychoactive. And CBD oil derived from hemp is particularly low in — in fact, hemp is (in part) legally defined by having no more than .3% of the chemical. Kush Mascara contains CBD-rich cannabis oil derived from hemp and does not contain THC.
Duchess was diagnosed with cancer in her right anal gland. When the cancer was removed it had spread to her left anal gland and was attached to her bowels. She was given 3 months to live. Since then I have had 2 vets check her glands and have had complete physical. She has a clean bill of health. I am so grateful to you. We are going to start on a maintenance program. I tell everyone how she has done. Thanks
Food and beverage products containing CBD were introduced in the United States in 2017. Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance. In the United States, numerous products are marketed as containing CBD, but in reality contain little or none. Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the Food and Drug Administration for making unsubstantiated health claims.
CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer .